29.60 0.00 (0.00%)
After hours: 4:49PM EST
|Bid||27.75 x 800|
|Ask||30.00 x 1300|
|Day's Range||29.20 - 29.74|
|52 Week Range||28.00 - 37.61|
|Beta (3Y Monthly)||N/A|
|PE Ratio (TTM)||107.25|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||34.87|
Investors need to pay close attention to Elanco Health (ELAN) stock based on the movements in the options market lately.
The drug giant announced on Friday that it will unload the remaining shares it holds of Elanco Animal Health through a voluntary stock-exchange offer.
Elanco Animal Health Incorporated (ELAN), formerly the animal health business of Eli Lilly and Company (Lilly), today announced it intends to file a Form S-4 Registration Statement with the Securities and Exchange Commission (SEC) in connection with Lilly’s proposed exchange offer whereby Lilly shareholders can exchange shares of Lilly common stock for shares of Elanco common stock owned by Lilly. The exchange offer is anticipated to be tax-free for participating Lilly shareholders in the United States, except with respect to cash received in lieu of fractional shares.
Eli Lilly and Co. said Friday it will divest its remaining stake in Elanco Animal Health via an exchange offer. Lilly shareholders will be able to exchange all, some of none of their shares of Lilly common stock for Elanco common stock owned by Lilly. The company retained an 80.2% stake, or 293.29 million shares, in the animal health company when it completed its IPO in September of 2018. "It's the right time to finalize the separation, let Elanco chart its future as a standalone company, and focus Lilly on our core mission to create human medicines that make life better for people around the world," Lilly Chief Executive David Ricks said in a statement. Lilly shareholders will be able to exchange their shares for Elanco shares at a 7% discount, subject to an upper limit of 4.5262 shares of Elanco stock per Lilly share. If the upper limit is not in effect, for each $100 of shares of Lilly common stock accepted in the exchange offer, tendering shareholders would receive approximately $107.53 of Elanco common stock. "These values will be determined by reference to the simple arithmetic average of the daily volume-weighted average prices of Lilly common stock and Elanco common stock on the New York Stock Exchange during the three consecutive trading days ending on and including the second trading day preceding the expiration date of the exchange offer, which would be March 4, March 5, and March 6, 2019, if the exchange offer is not extended or terminated," said the statement. Lilly shares rose 1.8% in premarket trade and have gained 58.3% in the last 12 months, while the S&P 500 has gained 4.9%.
INDIANAPOLIS, Feb. 8, 2019 /PRNewswire/ -- Eli Lilly and Company (LLY) announced it will initiate an exchange offer today to divest its remaining interest in Elanco Animal Health (ELAN). Elanco completed its initial public offering (IPO) in September 2018, with Lilly retaining an 80.2 percent ownership interest in Elanco. In the exchange offer, Lilly shareholders can exchange all, some or none of their shares of Lilly common stock for shares of Elanco common stock owned by Lilly, subject to possible proration as described below.
Full year global revenue increased 6 percent to $3.1 billion, Interceptor® Plus reaches blockbuster status with more than $100 million in annual sales
Eli Lilly and Company's (LLY) new drugs like Trulicity, Taltz and Jardiance are performing well. Let's see if these along with its older products lead the company to an earnings beat.
Elanco Animal Health (ELAN) has revised the date for its fourth-quarter and full-year 2018 financial results announcement. Elanco will also conduct a conference call with the investment community and media on that day to further detail the company's financial performance. Elanco (ELAN) is a global animal health company that develops products and knowledge services to prevent and treat disease in food animals and pets in more than 90 countries.
Performance Livestock Analytics, Inc. and Elanco Animal Health Incorporated , today announce an agreement to provide joint customers data from PLA’s fast-growing Performance Beef TM platform and access to Elanco’s Benchmark ® service.
The Zacks Analyst Blog Highlights: Intuitive Surgical, Illumina, HCA, Elanco Animal and Humana
Health-care stocks were the best sector in the Standard & Poor's 500-stock index in 2018, according to Yardeni Research. The sector's 4.7% gain last year isn't exactly eye-popping. But consider that utilities (+0.5%) were the only sector in the black, and that the index itself lost 6.2% ... and you realize just how impressive health care actually was. As we look ahead to 2019, economic storm clouds appear to be gathering. Although a recession is unlikely in the year ahead, UCLA economists estimate that GDP growth will shrink from 3% in 2018 to 2% in 2019 and finally 1% in 2020. Thus, in the potential absence of a good offense, it makes sense for investors to buy some defense in 2019. The best health-care stocks can fit that bill. "Health care is a defensive growth sector that we think should have a growth upturn over the next five years or so," Saira Malik, head of global equities at Nuveen, told Fortune in November. With that in mind, here are 10 health-care stocks to buy for 2019. ### SEE ALSO: 101 Best Dividend Stocks to Buy for 2019 and Beyond
Earnings per share (EPS) for 2019 are expected to be in the range of $0.36 to $0.48 on a reported basis and $1.02 to $1.12 on an adjusted basis. The company now expects 2018 EPS to be in the range of $0.15 to $0.17 on a reported basis. On an adjusted basis, the company reaffirms its expectation for 2018 EPS to be in the range of $1.14 to $1.16.
Elanco Animal Health Incorporated (ELAN) will announce its financial guidance for 2019 on Tuesday, Dec. 18, 2018. Elanco will also conduct a conference call that day with the investment community to further detail the company's financial guidance. The conference call will begin at 8:00 a.m. Eastern time.
Elanco Animal Health Incorporated (ELAN) and Farm Radio International (FRI) have partnered to produce a 13-week series of radio programs designed to support and educate small-scale livestock farmers in North Tanzania to manage the challenges around livestock health and wellbeing, supporting a drive to greater food security, livestock health and care in the region. FRI and Elanco are working closely with local radio stations - Sauti ya Injili and Loliondo FM - to produce a short series of interactive radio programs, enabling listeners to make informed decisions, and have access to relevant animal health care products and training.
NEW YORK, Nov. 20, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
Mallinckrodt soared early Tuesday after the pharma stock outperformed quarterly views, though Eli Lilly was more muted on its mixed report.
GREENFIELD, Ind.-- -- Third quarter revenue grew 9 percent to $761.1 million. Revenue, excluding strategic exits, grew 13 percent to $733.4 million; removing the impact of foreign currency exchange rates, growth was 15 percent. Reported net income grew $80.9 million in the third quarter to $60.2 million, which represents $0.16 per diluted share and $0.29 per diluted share on an adjusted basis. Delivered ...
The collaboration furthers Elanco’s commitment to antibiotic stewardship and offering alternatives to unmet needs. Elanco Animal Health Incorporated (ELAN), announced today a new global R&D collaboration with Novozymes A/S (OMX:NZYM B), the world leader in biological solutions, to develop nutritional health products for beef cattle and dairy cows globally. The effort will leverage Novozymes’ leading discovery and development programs, and together the companies will collaborate to develop a R&D pipeline and commercialize products in the next decade.
Elanco Animal Health Incorporated (ELAN), today named Todd S. Young as executive vice president and chief financial officer (CFO), joining Elanco’s Executive Committee and reporting to Elanco president and chief executive officer, Jeffrey N. Simmons. Young starts his new position at Elanco on November 1 at the company’s Greenfield, Indiana headquarters.